Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PALI-2108 in Healthy Volunteers and UC Patients
NCT06663605Phase 1Completed
- Sponsor
- Palisade Bio
- Start
- Nov 2024
- Primary completion
- Jul 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing PALI-2108 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Nov 2024; status: completed.
02
Drugs
PALI-2108
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06663605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663605.